Almirall SA · BME:ALM

Almirall SA — Merger or Acquisition (July 2007)

21 slides from Almirall SA's merger presentation, July 2007

  1. Slide 1: Almirall

    Zg . (& Almirall Solutions thinking of you

  2. Slide 2: Introduction

    Introduction 2

  3. Slide 3: Background

    Background ƒ Almirall recently completed its IPO and trading commenced on 20 June 2007 ƒ The strategy communicated at the time of IPO was to use the proceeds to fund business growth to 9 Increase international presence through partnerships and/or acquisitions 9 Leverage R&D pipeline ƒ Today, Almiral

  4. Slide 4: Key Transaction Highlights

    Key Transaction Highlights ƒ Hermal is the number 1 specialist prescription dermatology company in Germany with a leading position in the European dermatology market ƒ Hermal has 426 employees of which 11% are dedicated to R&D and 35% to sales & marketing ƒ Cash acquisition of 100% of Hermal from Re

  5. Slide 5: Strategic Rationale

    Strategic Rationale 1. Hermal is a solid and profitable business with strong track record of growth 2. Supports the build-up of a Pan-European presence and adds critical mass in Germany 3. Creates a leading dermatology/inflammatory indication platform, expands current product offering and allows for

  6. Slide 6: 1. Hermal

    1. Hermal 6

  7. Slide 7: Overview of Hermal

    Overview of Hermal ƒ Leading specialist prescription dermatology company in Europe ƒ Number 1 position in Germany ƒ Hermal has 426 employees and revenues of €102m in 2006 ƒ Strong brand and reputation amongst dermatology community ƒ Consistent detailing to specialist physicians ƒ Four core indicatio

  8. Slide 8: Selected Key Products

    Selected Key Products Product Comments Decoderm ƒ Number one GP dermatology product in Germany (Eczema) ƒ Unique first line treatment for inflamed and infected skin Balneum ƒ Europe’s number one medicated bath oil (Eczema) ƒ Hermal’s most well-known product ƒ Broad geographic reach Verrumal ƒ Europe

  9. Slide 9: Key Financials

    Key Financials Hermal Revenues (€m1) Comment 2 74 79 102 ƒ 7.6% revenue CAGR (2004-2006) 100.0 (excluding contract manufacturing 17 CAGR 7.6 % sales to RB) 5 80.0 2 1 ƒ 2006 EBITDA €22.6m 31 60.0 30 29 ƒ 2006 EBITDA margin 22% (and 26% excluding contract manufacturing 40.0 sales to RB) ƒ 47 49 44 20

  10. Slide 10: 2. Geographical expansion

    2. Geographical expansion 10

  11. Slide 11: Strong geographical fit

    Strong geographical fit ƒ Adds critical mass in Germany ƒ Entry into UK and Eastern Europe Hermal direct presence Almirall direct presence Almirall presence through partnerships 11

  12. Slide 12: Almirall continues its international expansion

    Almirall continues its international expansion • Opening of French • Opening of • Subsidiary • Signing of • Acquisition of subsidiary Italian established Pantopan Sofotec (acquisition of subsidiary in Germany agreement for (Germany) Acquisition of French company Italy and • Forest Hermal Pharmafarm

  13. Slide 13: 3. Dermatology

    3. Dermatology 13

  14. Slide 14: Attractions of Dermatology Market

    Attractions of Dermatology Market ƒ Key strategic market for Almirall 9 One product for psoriasis in phase II and several other dermatological programmes in discovery feasibility ƒ Specialist pharma market implying 9 Lower cost of detailing due to focus on high prescribing specialists 9 Less severe

  15. Slide 15: Leading position in Europe

    Leading position in Europe ƒ Number 1 prescription dermatology company in Germany and among the leading European dermatology players ƒ Unique and respected heritage – a trusted partner to the dermatology community ƒ Broad product portfolio with a range of different formulations ƒ Strong “Hermal” umb

  16. Slide 16: 4. Synergies

    4. Synergies 16

  17. Slide 17: Synergies

    Synergies ƒ Optimisation of international network ƒ Complimentary geographical footprints ƒ Cross-selling opportunities ƒ Complementary product development and formulation expertise ƒ Positive tax impact of goodwill amortisation ƒ Fully implemented in 2 years 17

  18. Slide 18: 5. Financial effects

    5. Financial effects 18

  19. Slide 19: Transaction Highlights

    Transaction Highlights Key terms ƒ Cash acquisition of 100% stake of Hermal for an Enterprise Value of €3761m / £255m ƒ Acquisition financed through internal resources and external bank facilities ƒ Hermal will enter into a 3 year contract manufacturing agreement with Reckitt Beckinser as part of th

  20. Slide 20: Conclusions

    Conclusions 20

  21. Slide 21: Conclusions

    Conclusions ƒ Large step towards Pan European presence 9 ƒ Increases weight of International sales in Almirall portfolio 9 ƒ Strengthens position in attractive dermatology franchise 9 ƒ Adds specialty pharma expertise and marketing power 9 ƒ Complementary formulation and development expertise 9 ƒ Re

Almirall — Merger or Acquisition (July 2007) on 6ix